Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients

Zachary A. Yetmar, Eric Bhaimia, Raymund R. Razonable

Research output: Contribution to journalReview articlepeer-review


Purpose of reviewCoronavirus disease-2019 (COVID-19) disproportionately causes severe outcomes in solid organ transplant recipients (SOTR). Antispike monoclonal antibodies have been authorized for therapy and prophylaxis for COVID-19. Here, we review the current state of antispike monoclonal antibodies and their role for SOTRs.Recent findingsBamlanivimab with or without etesevimab, casirivimab-imdevimab and sotrovimab have reduced the rates of hospitalization and severe disease in high-risk patients with mild-to-moderate COVID-19. Multiple retrospective studies have also demonstrated monoclonal antibodies are effective in SOTR populations. However, the evolution of resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concerns has resulted in revocation of the authorization of bamlanivimab with or without etesevimab, and casirivimab-imdevimab as treatment and postexposure prophylaxis (PEP). Sotrovimab and bebtelovimab are currently authorized for treatment of the predominant circulating SARS-CoV-2 B.1.1.529 (Omicron), but not as pre or PEP. Tixagevimab-cilgavimab, a long-acting antibody combination preparation, is authorized for preexposure prophylaxis in high-risk immunocompromised populations, including SOTRs, who are less likely to mount an effective immune response following vaccination series and booster.SummaryAntispike monoclonal antibodies are useful for the prevention and treatment of mild-to-moderate COVID-19 in SOTRs. However, their clinical use should be determined by the evolving epidemiology of SARS-CoV-2 variants in the community.

Original languageEnglish (US)
Pages (from-to)269-276
Number of pages8
JournalCurrent opinion in organ transplantation
Issue number4
StatePublished - Aug 1 2022


  • coronavirus disease-2019
  • monoclonal antibody
  • prophylaxis
  • severe acute respiratory syndrome coronavirus 2
  • solid organ transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation


Dive into the research topics of 'Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients'. Together they form a unique fingerprint.

Cite this